BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 36281973)

  • 21. Characterization of lean patients with nonalcoholic fatty liver disease: potential role of high hemoglobin levels.
    Akyuz U; Yesil A; Yilmaz Y
    Scand J Gastroenterol; 2015 Mar; 50(3):341-6. PubMed ID: 25540973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management.
    Chrysavgis L; Ztriva E; Protopapas A; Tziomalos K; Cholongitas E
    World J Gastroenterol; 2020 Nov; 26(42):6514-6528. PubMed ID: 33268944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical characterization and proteomic profiling of lean nonalcoholic fatty liver disease.
    Jiang Y; Zhuang X; Zhang J; Li M; Du S; Tian J; Yuan Y; Ji G; Hu C
    Front Endocrinol (Lausanne); 2023; 14():1171397. PubMed ID: 38034020
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Weight change and resolution of fatty liver in normal weight individuals with nonalcoholic fatty liver disease.
    Sinn DH; Kang D; Cho SJ; Paik SW; Guallar E; Cho J; Gwak GY
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e529-e534. PubMed ID: 33867441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between triglyceride glucose-body mass index and non-alcoholic fatty liver disease in the non-obese Chinese population with normal blood lipid levels: a secondary analysis based on a prospective cohort study.
    Li Y; Zheng R; Li J; Feng S; Wang L; Huang Z
    Lipids Health Dis; 2020 Oct; 19(1):229. PubMed ID: 33109219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined influence of nonalcoholic fatty liver and body size phenotypes on diabetes risk.
    Du T; Yu X; Yuan G; Zhang J; Sun X
    Cardiovasc Diabetol; 2015 Oct; 14():144. PubMed ID: 26511621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonalcoholic Fatty Liver Disease and Risk of Early-Onset Vasomotor Symptoms in Lean and Overweight Premenopausal Women.
    Cho Y; Chang Y; Choi HR; Kang J; Kwon R; Lim GY; Ahn J; Kim KH; Kim H; Hong YS; Zhao D; Rampal S; Cho J; Park HY; Guallar E; Ryu S
    Nutrients; 2022 Jul; 14(14):. PubMed ID: 35889762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gastrointestinal cancers in lean individuals with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Souza M; Diaz I; Barchetta I; Mantovani A
    Liver Int; 2024 Jan; 44(1):6-14. PubMed ID: 37833849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinctive clinical and genetic features of lean vs overweight fatty liver disease using the UK Biobank.
    Chahal D; Sharma D; Keshavarzi S; Arisar FAQ; Patel K; Xu W; Bhat M
    Hepatol Int; 2022 Apr; 16(2):325-336. PubMed ID: 35178663
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: A post hoc analysis of a cohort study.
    Yoshitaka H; Hamaguchi M; Kojima T; Fukuda T; Ohbora A; Fukui M
    Medicine (Baltimore); 2017 May; 96(18):e6712. PubMed ID: 28471965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative Burden of Metabolic Dysfunction in Lean NAFLD vs Non-lean NAFLD - A Systematic Review and Meta-analysis.
    Tang A; Ng CH; Phang PH; Chan KE; Chin YH; Fu CE; Zeng RW; Xiao J; Tan DJH; Quek J; Lim WH; Mak LY; Wang JW; Chew NWS; Syn N; Huang DQ; Siddiqui MS; Sanyal A; Muthiah M; Noureddin M
    Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1750-1760.e12. PubMed ID: 35863685
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Laboratory parameters in lean NAFLD: comparison of subjects with lean NAFLD with obese subjects without hepatic steatosis.
    Bernhardt P; Kratzer W; Schmidberger J; Graeter T; Gruener B;
    BMC Res Notes; 2018 Feb; 11(1):101. PubMed ID: 29409538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardiovascular Risk Is Elevated in Lean Subjects with Nonalcoholic Fatty Liver Disease.
    Kim Y; Han E; Lee JS; Lee HW; Kim BK; Kim MK; Kim HS; Park JY; Kim DY; Ahn SH; Lee BW; Kang ES; Cha BS; Lee YH; Kim SU
    Gut Liver; 2022 Mar; 16(2):290-299. PubMed ID: 34238770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
    Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.
    Ye Q; Zou B; Yeo YH; Li J; Huang DQ; Wu Y; Yang H; Liu C; Kam LY; Tan XXE; Chien N; Trinh S; Henry L; Stave CD; Hosaka T; Cheung RC; Nguyen MH
    Lancet Gastroenterol Hepatol; 2020 Aug; 5(8):739-752. PubMed ID: 32413340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities.
    Wijarnpreecha K; Li F; Lundin SK; Suresh D; Song MW; Tao C; Chen VL; Lok ASF
    Aliment Pharmacol Ther; 2023 May; 57(9):1014-1027. PubMed ID: 36815445
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of genetic variations with NAFLD in lean individuals.
    Lin H; Wong GL; Whatling C; Chan AW; Leung HH; Tse CH; Shu SS; Chim AM; Lai JC; Yip TC; Wong VW
    Liver Int; 2022 Jan; 42(1):149-160. PubMed ID: 34610207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lean non-alcoholic fatty liver disease (lean NAFLD): characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka.
    Niriella MA; Kasturiratne A; Pathmeswaran A; De Silva ST; Perera KR; Subasinghe SKCE; Kodisinghe SK; Piyaratna TACL; Vithiya K; Dassanayaka AS; De Silva AP; Wickramasinghe AR; Takeuchi F; Kato N; de Silva HJ
    Hepatol Int; 2019 May; 13(3):314-322. PubMed ID: 30539516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fecal and blood microbiota profiles and presence of nonalcoholic fatty liver disease in obese versus lean subjects.
    Yun Y; Kim HN; Lee EJ; Ryu S; Chang Y; Shin H; Kim HL; Kim TH; Yoo K; Kim HY
    PLoS One; 2019; 14(3):e0213692. PubMed ID: 30870486
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities.
    Golabi P; Paik JM; Arshad T; Younossi Y; Mishra A; Younossi ZM
    Hepatol Commun; 2020 Aug; 4(8):1136-1148. PubMed ID: 32766474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.